|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Treatment of dyslipidemia in chronic kidney disease: Effectiveness and safety of statins显示文摘Several cardiovascular(CV)risk factors may explain the high rate of CV death among patients with chronic kidney disease(CKD).Among them both traditional and uremia-related risk factors are implicated and,moreover,the presence of kidney disease represents'per se'a multiplier of CV risk.Plasma lipid and lipoprotein profiles are changed in quantitative,but above all in qualitative,structural,and functional ways,and lipoprotein metabolism is influenced by the progressive loss of renal function.Statin therapy significantly reduces cholesterol synthesis and both CV morbidity and mortality either directly,by reducing the lipid profile,or via pleiotropic effects;it is supposed to be able to reduce both the progression of CKD and also proteinuria.These observations derive from a post-hoc analysis of large trials conducted in the general population,but not in CKD patients.However,the recently published SHARP trial,including over 9200 patients,either on dialysis or pre-dialysis,showed that simvastatin plus ezetimibe,compared with placebo,was associated with a significant low-density lipoprotein cholesterol reduction and a 17%reduction in major atherosclerotic events.However,no benefit was observed in overall survival nor in preserving renal function in patients treated.These re-cent data reinforce the conviction among nephrologists to consider their patients at high CV risk and that lipid lowering drugs such as statins may represent an important tool in reducing atheromatous coronary disease which,however,represents only a third of CV deaths in patients with CKD.Therefore,statins have no protective effect among the remaining two-thirds of patients who suffer from sudden cardiac death due to arrhythmia or heart failure,prevalent among CKD patients.The safety of statins is demonstrated in CKD by several trials and recently confirmed by the largest SHARP trial,in terms of no increase in cancer incidence,muscle pain,creatine kinase levels,severe rhabdomyolysis,hepatitis,gallstones and pancreatitis;thus confirming the handiness of statins in CKD patients.Here we will review the latest data available concerning the effectiveness and safety of statin therapy in CKD patients. | Roberto Scarpioni Marco Ricardi Vittorio Albertazzi Luigi Melfa | 2012 | World Journal of Nephrology2012，1，6： | 10 |
| 2 | Secondary amyloidosis in autoinflammatory diseases and the role of inflammation in renal damage显示文摘The release of proinflammatory cytokines during inflam-mation represents an attempt to respond to injury, but it may produce detrimental effects. The inflammasome is a large, multiprotein complex that drives proinflammatory cytokine production in response to infection and tissue injury; the best-characterized inflammasome is the nod-like receptor protein-3(NLRP3). Once activated, inflammasome leads to the active form of caspase-1, the enzyme required for the maturation of interleukin-1beta. Additional mechanisms bringing to renal inflammatory, systemic diseases and fibrotic processes were recently reported, via the activation of the inflammasome that consists of NLRP3, apoptosis associated speck-like protein and caspase-1. Several manuscripts seem to identify NLRP3 inflammasome as a possible therapeutic target in the treatment of progressive chronic kidney disease. Serum amyloid A(SAA), as acute-phase protein with also proinflammatory properties, has been shown to induce the secretion of cathepsin B and inflammasome components from human macrophages. SAA is a well recognised potent activator of the NLRP3. Here we will address our description on the involvement of the kidney in autoinflammatory diseases driven mainly by secondary, or reactive, AA amyloidosis with a particular attention on novel therapeutic approach which has to be addressed in suppressing underlying inflammatory disease and reducing the SAA concentration. | Roberto Scarpioni Marco Ricardi Vittorio Albertazzi | 2016 | World Journal of Nephrology2016，5，1： | 4 |
| 3 | Critical review of health effects of soyabean phyto-oestrogens in post-menopausal women显示文摘 | Cassidy A Albertazzi P Lise Nielsen I | 2006 | Proc Nutr Soc2006，65，1： | 1 |
| 4 | 显示文摘 | ALBERTAZZI E DOMENE C FOWLER P W | 1999 | Phys Chem Chem Phys1999，1，： | 1 |
| 5 | Characterization of a sphce variant of metastasis-associated h-mtsl(S100A4) gene expressed in human infiltrating carcinomas of the breast显示文摘 | Albertazzi E Cajone F Lakshmi MS et at | 1998 | DNA Ceil Biol1998，17，12： | 1 |
| 6 | The Impact of the Sovereign Debt Crisis on the Activity of Italian Banks 显示文摘 | Ugo Albertazzi Tiziano Ropele Gabriele Sene Federico Maria Signoretti | 2014 | Journal of Banking & Finance2014，46，： | 1 |
| 7 | Determination of He electronic energy loss in crystalline Si by Monte-Carlo simulation of Rutherford backscattering- channeling spectra 显示文摘 | LULLI G ALBERTAZZI E BIANCONI M | 2000 | Nuclear Instruments and Meth- ods in Physics Research Section B: Beam Interactions with Materials and Atoms2000，170，12： | 1 |
| 8 | Tibolone: a review显示文摘 | Paola Albertazzi Raffaele Di Micco Ettore Zanardi | 1998 | Maturitas1998，30，： | 1 |
| 9 | Noradrenergic and serotonergic modulation to treat vasomotor symptoms显示文摘 | Albertazzi P | 2006 | J Br Menopause Soc2006，12，1： | 1 |
| 10 | The technical feasibility of biomass gasification for hydrogen production 显示文摘 | Albertazzi S Basile F Brandin J | 2005 | Catalysis Today2005，106，： | 1 |
| 11 | Gabapentin for the man- agement of hot flushes : a case series 显示文摘 | Albertazzi P Bottazzi M Purdie DW | 2003 | Menopause2003，10，： | 1 |
| 12 | High diversity of genes for nonhost resistance of barley to heterologous rust fungi显示文摘 | Jafary H Albertazzi G Marcel T C | 2008 | Genetics2008，178，： | 1 |
| 13 | The effect of dietary soy supplementation on hot flashes 显示文摘 | Albertazzi P Pansini F Bonaccorsi G | 1998 | Obstet Gynecol1998，91，1： | 1 |
| 14 | Effects of pure genistein on bone markers and hot flushes显示文摘 | Steel S A | 2005 | Climacteric2005，8，4： | 1 |
| 15 | Bone mineral density and depot medroxyprogesterone acetate显示文摘 | Albertazzi P Botazzi M Steel SA | 2006 | Contraception2006，73，6： | 1 |
| 16 | Dyslipidemia and the risk of kidney disease显示文摘 | Ligabue G Cavazzini F Albertazzi A | 2007 | G Ital Nefrol2007，24，38： | 1 |
| 17 | Hydrogenation of naphthalene on Pd/Pt supported on zirconium-doped mesoporous silica catalysts显示文摘 | Albertazzi S Rodriguez-Castell6n E Livi M | 2004 | Journal of Catalysis2004，228，1： | 1 |
| 18 | Deactivation of a Pt/γ-Al 2 O 3 catalyst in the partial oxidation of methane to synthesis gas显示文摘 | S Albertazzi P Arpentinier F Basile P Del Gallo G Fornasari D Gary A Vaccari | 2003 | Applied Catalysis A General2003，，1： | 1 |
| 19 | Clinical experience with PMMA membrane显示文摘 | ALBERTAZZI A BONOMINI M | 1999 | Contrib Nephrol1999，125，： | 1 |
| 20 | The effect of dietary soy supplementation on hot flushes 显示文摘 | Albertazzi P Pansini F Bonaccorsi G | 1998 | Obstet Gynecol1998，91，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员